Erythromycin Ophthalmic Ointment
Primary Indication and Dosing
Erythromycin 0.5% ophthalmic ointment is indicated for neonatal prophylaxis against ophthalmia neonatorum and for treating superficial bacterial conjunctivitis caused by susceptible organisms. 1, 2
Neonatal Prophylaxis (Ophthalmia Neonatorum)
- Dosing: Apply a 1 cm ribbon of 0.5% ointment into each lower conjunctival sac as a single application at birth 1, 2
- Use a new tube for each infant to prevent cross-contamination 2
- This prevents gonococcal and chlamydial ophthalmia neonatorum 2
Critical caveat: Topical erythromycin prophylaxis alone is inadequate for infants born to mothers with clinically apparent gonorrhea. These infants require systemic therapy with aqueous crystalline penicillin G (50,000 units IM/IV for term infants or 20,000 units for low birth weight infants) 2
Treatment of Bacterial Conjunctivitis
- Dosing: Apply approximately 1 cm ribbon directly to infected eye(s) up to 6 times daily, depending on infection severity 2
- Duration: Typically 7 days 2
- Do not flush the ointment from the eye after instillation 2
Treatment of Neonatal Chlamydial Conjunctivitis
When neonatal chlamydial conjunctivitis is diagnosed, systemic oral erythromycin is required, not topical ointment. 1
- Oral erythromycin base or ethylsuccinate: 50 mg/kg body weight/day divided into 4 doses daily for 14 days 1
- Alternative: Azithromycin suspension: 20 mg/kg/day orally once daily for 3 days 1
- Cure rates with oral erythromycin 50 mg/kg/day for 14 days: Clinical cure 96% (95% CI 94-100%), microbiological cure 97% (95% CI 95-99%) 3
Major safety warning: Oral erythromycin in infants <6 weeks old is associated with infantile hypertrophic pyloric stenosis. Monitor these infants closely for signs and symptoms 1
Contraindications and Limitations
Resistance Concerns
Erythromycin demonstrates high levels of resistance among conjunctival bacterial isolates 4. A decade-long surveillance study showed erythromycin had among the highest resistance rates, along with tetracycline and trimethoprim/sulfamethoxazole 4. This makes erythromycin a poor choice for empirical treatment of bacterial conjunctivitis in older children and adults.
Specific Limitations
- Not effective against penicillinase-producing N. gonorrhoeae for prophylaxis 2
- Should not be used as monotherapy for gonococcal conjunctivitis—requires systemic ceftriaxone 1
- Limited spectrum compared to fluoroquinolones (moxifloxacin, gatifloxacin) which show lowest broad-spectrum resistance 4
Clinical Context
While antibiotics modestly improve clinical remission rates in bacterial conjunctivitis (RR 1.36 at days 2-5, RR 1.21 at days 6-10) 5, 41% of placebo-treated cases resolve spontaneously by days 6-10 5. Given erythromycin's high resistance rates 4, it should be reserved primarily for neonatal prophylaxis where it remains the standard of care 1.
For empirical treatment of bacterial conjunctivitis in non-neonates, newer fluoroquinolones (moxifloxacin, gatifloxacin) or aminoglycosides demonstrate superior susceptibility profiles 4.